Pharmaceuticals & Biotech U.S. Community

Prologue: Witnessing the Exosome Revolution in Clinical Practice As a veterinarian actively running a clinic in 2026, I have seen firsthand the disruptive power of exosome technology. Last year, I introduced an 'exosome ice-needling injection machine' at my hospital to treat some of the most stubborn conditions in small animals.Read more

Aurinia bets on one drug for lupus kidney disease, and that narrow focus is starting to look more like discipline than a weakness as doctors use it more and insurance coverage settles. The big question is whether new regions can add growth before competition, pricing pressure, or its thin pipeline catches up.Read more

After a rocky early launch, Iovance now has a cancer treatment already cleared for use, and the story shifts from “will it work?” to “can it catch on” as more hospitals come on board and manufacturing improves. If results in other hard-to-treat cancers hold up, the company could grow far beyond melanoma—and it may even draw interest from a bigger drugmaker looking to fill future gaps.Read more

Rocket Pharma may look like an early-stage biotech, but it already has a proven way to make and scale its gene therapies in-house—something the market often overlooks. A big upcoming clinical readout could confirm a second technology platform and force investors to rethink what this business is worth.Read more

MindWalk is no longer just a lab-for-hire biotech company; it is building a software platform that helps drug teams predict what molecules will do, and the market may not be keeping up with that shift. The upside hinges on whether big customers adopt its LensAI platform and whether its vaccine and metabolic drug candidates prove out without forcing shareholders to fund endless experiments.Read more

Optimi Health already makes and ships controlled psychedelic medicines to paying clinics, while most rivals are still waiting for approvals. The story hinges on whether a real, insured market can scale fast enough to fill its underused factory—before funding and rule changes become a problem.Read more

Tempus AI is quietly turning genetic tests and clinical records into a healthcare data platform that drugmakers and hospitals can plug into, making the system more useful every time it’s used. With growth holding up, costs improving, and big-name funds taking notice, the bigger question is whether its debt and high expectations around AI could still trip it up.Read more

Conexeu is building an injectable material that turns into a gel inside the body, aiming to help damaged tissue rebuild itself instead of just being covered up. The big question is whether it can clear regulators and win adoption in wound care first—then expand into areas like dentistry, animal health, and even cosmetic use.Read more

Zoetis makes medicines for pets and farm animals, but a sharp slowdown in its US pet business recently rattles investors and raises questions about how durable demand really is. The story hinges on whether its long track record of steady pricing and buybacks can keep the business resilient—or whether debt, product concentration, and copycat drugs start to bite.Read more